Kontafarma China Holdings Dividend

Dividend criteria checks 0/6

Kontafarma China Holdings does not have a record of paying a dividend.

Key information

Dividend yield

Payout ratio

Industry average yield	3.5%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-HK$0.0052
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 1312's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1312's dividend payments have been increasing.

Dividend Yield vs Market

Kontafarma China Holdings Dividend Yield vs Market

How does 1312 dividend yield compare to the market?
Segment	Dividend Yield
Company (1312)	0%
Market Bottom 25% (HK)	3.2%
Market Top 25% (HK)	8.0%
Industry Average (Pharmaceuticals)	3.5%
Analyst forecast in 3 Years (1312)	n/a

Notable Dividend: Unable to evaluate 1312's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1312's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: 1312 is not paying a notable dividend for the Hong Kong market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 1312 has not reported any payouts.

Kontafarma China Holdings Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

New minor risk - Share price stability

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024

Full year 2023 earnings released: HK$0.005 loss per share (vs HK$0.015 loss in FY 2022)

Kontafarma China Holdings Limited, Annual General Meeting, Jun 07, 2024

Kontafarma China Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

First half 2023 earnings released: EPS: HK$0.007 (vs HK$0.009 loss in 1H 2022)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Kontafarma China Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New major risk - Share price stability

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Full year 2022 earnings released: HK$0.015 loss per share (vs HK$0.003 loss in FY 2021)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Less than half of directors are independent

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

First half 2022 earnings released: HK$0.011 loss per share (vs HK$0.014 loss in 1H 2021)

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022

Less than half of directors are independent

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Tongfang Kontafarma Holdings Limited Announces Management Changes

Full year 2021 earnings released: HK$0.003 loss per share (vs HK$0.008 loss in FY 2020)

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Executive Director Bingzhang Wei has left the company

Less than half of directors are independent

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Tongfang Kontafarma Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Minyi Holdings Limited entered into an agreement to acquire Real Jade Limited from Tongfang Kontafarma Holdings Limited (SEHK:1312) for approximately HKD 350 million.

First half earnings released

First half earnings released

Tongfang Kontafarma Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies